NEW YORK (GenomeWeb) – The Centers for Medicare & Medicaid Services last week released preliminary gapfill rates for 2017 from its Medicare Administrative Contractors (MAC) for a number of molecular diagnostic tests.

CMS' proposed median payment would reduce pricing for CareDx's AlloMap by 74 percent to $732; Veracyte's Afirma GEC by 30 percent to $2,240; and Genomic Health's Oncotype DX Colon by 72 percent to $849. CMS has proposed to essentially maintain pricing for Myriad Genetics' Vectra DA at $587.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Jul
24
Sponsored by
Qiagen

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Jul
25
Sponsored by
Streck

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms. 

Aug
09

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.